Exelon - Rivastigmine
4 customer reviewsExelon is a rivastigmine medicine used for dementia linked to Alzheimer’s disease and Parkinson’s disease. It is for adults who need support with memory, thinking, and daily functioning. It helps by slowing the breakdown of acetylcholine in the brain.
What is it?
Exelon is a rivastigmine-containing medicine prescribed for dementia symptoms in Alzheimer’s disease and Parkinson’s disease dementia. It does not cure the underlying disease, yet it can help some patients maintain cognition and day-to-day activities for longer.
Composition
Exelon, containing the active ingredient rivastigmine, is a medicine used to treat dementia linked to Alzheimer’s disease and Parkinson’s disease.
How to use?
Dosing is individualised and is usually titrated upward in steps to reduce stomach side effects and dizziness. This is one of those medicines where “start low, go slow” is not a slogan—it prevents dropouts from nausea.
Typical administration approach for capsules:
- Taken with food, usually morning and evening.
- Dose increases are separated by weeks, not days.
- If treatment is interrupted for several days, clinicians often restart at a lower dose and re-titrate rather than resuming the previous dose.
Missed dose rules used in practice:
- If a dose is missed, take the next scheduled dose at the usual time.
- Avoid doubling the next dose, since that raises the risk of vomiting, fainting, and slow heart rate.
Some sources describe Exelon as requiring a physician’s prescription for safe titration and monitoring, even when local dispensing rules vary [2].
How does it work?
- Route: oral tablets; take by mouth.
- Dose: start with 1.5 mg twice daily, then increase to 3 mg twice daily, 4.5 mg twice daily, and 6 mg twice daily if tolerated.
- Frequency: 2 times/day.
- Timing: take with food, preferably with the morning and evening meals.
- Duration: continue daily long term as prescribed; dose changes are usually made every at least 2 weeks based on tolerability.
Indications
Exelon is a rivastigmine-containing medicine prescribed for dementia symptoms in Alzheimer’s disease and Parkinson’s disease dementia. It does not cure the underlying disease, yet it can help some patients maintain cognition and day-to-day activities for longer.
Comparison
People shopping for Exelon often want to understand how rivastigmine fits against other dementia medicines. The key difference is mechanism and tolerability profile, not “stronger vs weaker”.
| Option (active ingredient) | How it works | When it’s often chosen |
|---|---|---|
| Rivastigmine (Exelon) | Cholinesterase inhibition (AChE + BuChE) | Alzheimer’s dementia; Parkinson’s disease dementia; when a cholinesterase inhibitor is appropriate |
| Donepezil | Cholinesterase inhibition (AChE) | Alzheimer’s dementia; once-daily routine suits many patients |
| Memantine | NMDA receptor modulation | Moderate to severe Alzheimer’s; used alone or with a cholinesterase inhibitor |
Rivastigmine’s “two-enzyme” inhibition is a pharmacology detail many patients never hear, yet it explains why response can differ between rivastigmine and donepezil even though both are in the same broad class. Memantine tends to be used later in the disease course, and it does not share the same nausea-and-weight-loss pattern as strongly.
Contraindications
Exelon is NOT for you if any of the following apply:
- Allergy or hypersensitivity to rivastigmine.
- Severe liver dysfunction, where drug handling can be impaired.
- Active or recent peptic ulcer disease or GI bleeding risk that is not controlled.
- Marked bradycardia or clinically significant heart rhythm disorders.
Interactions and caution points that often matter in real patients:
- Other drugs that lower heart rate (for example beta-blockers) can add to bradycardia risk.
- Anticholinergic medicines (used for overactive bladder, some antihistamines, some anti-nausea agents) can oppose the cognitive effect and create a “push-pull” problem.
- Planned surgery: cholinesterase inhibitors can interact with some anaesthetic medicines, so anaesthetists usually want it documented in the medication list.
Not recommended for
Exelon is not a good fit if you have a history of severe stomach bleeding, a very slow pulse, or serious rhythm problems. It also needs extra caution if you already take medicines that slow the heart or if nausea and weight loss would be hard for you to tolerate.
Side effects
Gastrointestinal side effects are the main reason people struggle early on: nausea, vomiting, diarrhoea, abdominal discomfort, and reduced appetite. Dizziness and headache also occur, and they can raise fall risk in older adults.
- Slow heart rate (bradycardia), fainting (syncope), or worsening conduction problems can occur, especially in people already on beta-blockers or with known rhythm issues.
- Significant weight loss can develop over weeks to months and can matter clinically in frail patients.
- Severe GI reactions (persistent vomiting, dehydration, bleeding) can become dangerous; regulatory discussions describe serious GI reactions as potentially fatal when dehydration or complications develop [3].
Common mistakes
These are patterns pharmacists see repeatedly with Exelon capsules:
- Stopping after 2–3 days because of nausea, without trying food timing or slower titration.
- Restarting at the old dose after a gap of several days, which often triggers intense vomiting and dizziness.
- Taking doses on an empty stomach to “absorb better”, then blaming the medicine for intolerance.
- Ignoring fainting, new slow pulse, or black stools, assuming they are “just age-related”.
- Mixing up “memory seemed worse” during an intercurrent illness (UTI, dehydration, poor sleep) with medicine failure and escalating doses too quickly.
Doctor opinions
A final real-world point: if weight loss begins, clinicians take it seriously. It can be a direct drug effect (less appetite, more nausea) or a sign the patient needs more feeding support.
Frequently asked questions
Most families look for early tolerability first, then for cognitive or functional changes over the next several weeks. A measurable effect is often assessed at follow-up visits after titration steps are completed. The WHO describes dementia care as combining medicines with caregiver support and safety planning, since medication benefit is usually modest and symptom-focused [4].
Yes. Rivastigmine is one of the better-known options for dementia symptoms associated with Parkinson’s disease, where attention fluctuations and visual hallucinations can coexist with memory problems. Neurology follow-ups often focus on balancing cognition against side effects like dizziness and nausea. EMA product assessments include Parkinson’s disease dementia within the evaluated indications for rivastigmine-containing products.
After a gap of several days, restarting at the previous full dose can trigger strong nausea and vomiting, and sometimes marked dizziness. Clinicians often re-start at a lower dose and titrate again to regain tolerance. This approach mirrors how cholinesterase inhibitors are introduced in standard prescribing guidance rather than treating missed doses like a one-off slip.
Acid-reducing therapy does not address the core nausea mechanism of cholinesterase inhibitors, so it may not solve symptoms on its own. Food timing, slower titration, and hydration tend to be more impactful for rivastigmine-related nausea. If there is ulcer disease history or GI bleeding risk, prescribers factor that into the decision to use Exelon and into monitoring intensity.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Exelon — Comparison with alternatives
Exelon Current
Memantine
Modalert Best rated
Azilect Best price
Brahmi
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2024). Exelon (rivastigmine) — EPAR (European Public Assessment Report). ↑
- National Institute for Health and Care Excellence (NICE) (2018). Dementia: assessment, management and support for people living with dementia and their carers (NG97). ↑
- U.S. Food and Drug Administration (FDA) (2023). Rivastigmine — Prescribing Information (label). ↑
- World Health Organization (WHO) (2023). Dementia — Fact sheet. ↑
- MOHAP (Ministry of Health and Prevention, UAE) (2022). Medication safety: guidance for patients and caregivers. ↑